Litcius/Paper detail

Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5–11 years in Italy: a retrospective analysis of January–April, 2022

Chiara Sacco, Martina Del Manso, Alberto Mateo‐Urdiales, Maria Cristina Rota, Daniele Petrone, Flavia Riccardo, Antonino Bella, Andrea Siddu, Serena Battilomo, Valeria Proietti, Patrizia Popoli, Francesca Menniti‐Ippolito, Anna Teresa Palamara, Silvio Brusaferro, Giovanni Rezza, Patrizio Pezzotti, Massimo Fabiani

2022The Lancet125 citationsDOIOpen Access PDF

Topics & Concepts

MedicineVaccinationPediatricsContext (archaeology)EpidemiologyRetrospective cohort studyCoronavirus disease 2019 (COVID-19)PopulationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Public healthVaccination policyEnvironmental healthImmunologyInternal medicineDiseaseBiologyPaleontologyNursingInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyImmune responses and vaccinations
Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5–11 years in Italy: a retrospective analysis of January–April, 2022 | Litcius